TAM phenotypes may differ among cancer types, individual patients, and even location within the tumor, simply defining TAMs based on the classical versus alternatively activated phenotype has its limitations. TAMs comprise heterogeneous populations with diverse and mixed phenotypes. 4 In mice, TAMs are identified in tumors as F4/80 1 and CD11b
1
. In humans, TAMs are identified as CD68
1 by immunohistochemistry and CD14
1 by flow cytometry. Additional markers used to define HCC TAMs include human leukocyte antigen (HLA)-DR 1 
, CD163
1 , CD206
1
, and high arginase activity. Frequency of infiltrating TAMs is correlated with poor prognosis in HCC. 5 Thus, a better understanding of TAMs will be important for developing future therapy for treating patients with HCC.
MDSCs
In cancer, differentiation of myeloid cells is often altered, generating a population of immature myeloid cells with potent immunosuppressive activities and impaired function as antigen-presenting cells (APCs). 6 These cells are now known as MDSCs, which are a heterogeneous population of immature myeloid cells. 
HLA-DR
2 (granulocytic MDSCs). 9 Similar to TAMs, MDSCs are also plastic in response to microenvironmental signals. MDSCs can differentiate into macrophages, granulocytes, and DCs in vitro. 10 In the presence of tumor-derived factors or hypoxia, MDSCs can differentiate toward immunosuppressive TAMs. 11 In summary, MDSCs and TAMs are notably diverse and plastic cells that are able to shift their functional state in response to numerous cytokines and growth factors in the tumor microenvironment. MDSCs and TAMs show considerable overlapping phenotype and functions, including inhibition of effector T cells, production of immunosuppressive cytokines, and promotion of angiogenesis. Yet, studies in HCC also demonstrate a variety of distinct mechanisms for their immunosuppressive and tumor-promoting functions. Fig. 1 . Classically activated M1 and alternatively activated M2 macrophages. Macrophages originate from myeloid progenitors and circulating monocytes. Macrophages are incredibly plastic in response to various environmental stimuli and can be in a spectrum of functional states. The two polarization states at the extreme end are the classical activation state (M1) and the alternative activation state (M2). LPS and IFN-c generate classically activated M1 macrophages, which has proinflammatory activities, express high HLA-DR and IL-12, and stimulate effector T-cell function. IL-4, IL-10, and IL-13 generate alternatively activated M2 macrophages, which produce low IL-12, high IL-10 and PD-L1 (B7-H1), and have immunosuppressive functions.
Myeloid Cells and HCC Development
The link between TAMs and HCC development has been examined in various mouse models (Table 1 ). In the Md2-knockout mouse model, mice spontaneously develop cholestatic hepatitis followed by HCC. Tumor necrosis factor alpha (TNF-a) produced by TAMs and endothelial cells (ECs) activates nuclear factor kappa B (NF-jB), which protects hepatocytes from apoptosis and promotes tumor growth. 12 In the chemical carcinogen diethylnitrosamine (DEN)-driven HCC model, TAMderived TNF-a and IL-6 accelerate hepatocyte proliferation, leading to hepatocarcinogenesis. 13 Similar to human HCC, DEN-driven HCC in mice show gender disparity, with 100% HCC incidence in male mice and only 10%-30% HCC incidence in female littermates. This gender disparity is largely the result of higher MyD88-dependent IL-6 production by resident hepatic macrophages in male mice than in female mice. IL-6 promotes compensatory hepatocyte proliferation in response to DEN-induced tissue damage, which plays a critical role in DEN-induced HCC. Estrogen, at the concentrations present in females, inhibited IL-6 production by macrophages by decreasing activation of transcription factors NF-jB and CCAAT/ enhancer-binding protein (C/EBP)b, resulting in less incidence of HCC initiation in females.
14 Macrophages are activated, in part, by necrotic hepatocyte-derived high-mobility group box, which binds to the triggering receptor expressed on myeloid cells 1 (TREM-1). TREM-1 2/2 mice showed reduced proinflammatory cytokines IL-1b, IL-6, TNF, CCL2, and C-X-C motif chemokine (CXCL)10, as well as decreased DENinduced liver damage, compensatory hepatocyte proliferation, and liver tumorigenesis. 15 All together, these studies support that TAM-derived cytokines play a pivotal role in HCC development and progression.
MDSCs also accumulate in mouse HCCs, but vary in different HCC models. 16 Orthotopic and subcutaneous tumors derived from mouse HCC cell lines rapidly induced MDSC expansion in liver, spleen, and blood. In contrast, in the slow-growing DEN-driven HCC or MYC-expressing spontaneous HCCs, MDSCs only increased in advanced HCC. 16 How MDSCs are involved in HCC development awaits further investigation.
Myeloid Cells and HCC Angiogenesis
Angiogenesis plays a critical role in HCC progression. HCC tumors show extensive vasculature that provides nutrients for tumor growth. Sorafenib, a multikinase inhibitor, is the only U.S. Food and Drug Administration (FDA)-approved drug for advanced HCC. Indeed, sorafenib inhibits vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) signaling important for angiogenesis, along with the mitogen-activated protein kinase pathway for cell proliferation. Thus, drugs targeting angiogenesis show potential for treating HCC. Clinical evidence has shown a positive correlation between the frequency of TAMs and the density of microvessels, suggesting a role for TAMs in angiogenesis. TAMs secrete growth factors, including TGF-b, VEGF, fibroblast growth factor, PDGF, angiogenic factor thymidine phosphorylate, and angiogenesismodulating enzymes cyclooxygenase-2 and matrix metalloproteinases (MMPs), including MMP-2, MMP-7, MMP-9, and MMP-12, which promote migration of ECs and angiogenesis. 17 Similar to TAMs, MDSCs can directly promote tumor angiogenesis through producing high levels of MMP-9. 18 In an HCC xenograft model, sorafenib treatment inhibits tumor growth and lung metastasis, but also increases intratumoral TAM infiltration. TAM infiltration is accompanied by increased TAM chemoattractant colony-stimulating factor 1 (CSF-1) and angiogenic factors stromal cell-derived factor 1 alpha (SDF-1a) and VEGF. TAM depletion by zoledronic acid (ZA) or clodronate-encapsulated liposomes (clodrolip), in combination with sorafenib, further reduced tumor growth, lung metastasis, and tumor angiogenesis. 19 Hence, therapies disrupting TAMs is worthy of future studies to enhance the antitumor efficacy of sorafenib.
TAMs are preferentially attracted to hypoxic areas in tumor. Hypoxia-induced factor 1 alpha in TAMs is essential for TAM infiltration and activation in vivo. 20 In addition, hypoxia stimulates TAM chemokine production, including CCL2, CCL5, IL-8 (CXCL8), CXCL10, CXCL12, and CXCL13, that are involved in angiogenesis and tumor progression. For example, IL-8 promotes angiogenesis and is an independent predictor of mortality in early-stage HCC patients. 21 Various TAM subsets have been described based on surface marker expression. One of the subsets is tyrosine kinase with Ig and EGF homology domains 2 (TIE2)-expressing macrophages, which exerts proangiogenic activity. TIE2 is a receptor of angiopoietins. TIE2-expressing TAMs selectively migrate toward angiopoietin 2 released by ECs, especially in hypoxic tumor areas. 22 In HCC, frequency of TIE2-expressing TAMs is positively correlated with microvessel density and may serve as diagnostic marker for HCC. 23 This suggests that TAMs are involved in angiogenesis through a network of angiogenic signaling in the HCC microenvironment.
Myeloid Cells and HCC Metastasis
TAMs can facilitate tumor invasion and metastasis. Whereas TAMs are noted in almost all HCC patients, higher TAM densities correlate with other known HCC prognostic factors, such as tumor size, vascular invasion, number of tumor nodules, and tumor node metastasis (TNM) stage. Thus, both overall survival and diseasefree survival are negatively correlated with degree of TAM infiltration. 24 High expression of peritumoral CSF-1, an important macrophage growth factor and chemoattractant, correlates with poor prognosis in HCC patients. 24 Livers bearing metastatic HCC also show higher CSF-1 gene expression, compared to livers bearing nonmetastatic HCC. 25 Tumor-derived CSF-1 stimulates TAMs to produce epidermal growth factor, which attracts tumor cells and augment metastasis. TAMs are often found at the invasive front of advanced tumors. TAMs can promote tumor invasion through their matrix remodeling capability. TAMs secrete proteases MMPs, serine proteases, and cysteine cathepsins, which cleave components of the extracellular matrix and basement membrane and disrupt cell adhesion junctions, facilitating tumor cell invasion and metastasis. 26 ,27 MMP-9 overexpression is associated with higher invasive potential of HCC. 28 TAMs are identified as the main MMP-9-expressing cells at the invasive tumor front in a mouse HCC model. 29 Active tumor-and stromaderived MMP-9 can enzymatically cleave basement membrane proteins, increased at the HCC invasive front, and is significantly associated with cancer invasion to the HCC capsule and portal veins. 30 Whereas TAM recruitment to the peritumoral stroma has prognostic significance in HCC, the underlying mechanisms of the roles of TAMs and MDSCs on HCC invasiveness and metastasis require further investigation.
Myeloid Cells and HCC EpithelialMesenchymal Transition and Stemness
Recent findings suggest that TAMs can enhance cancer cell migration and invasion through direct influence on cancer cell phenotypic plasticity. CD163
1 TAMs enhanced migration capacities of HCC tumor cells and lung metastasis; one of the underlying mechanisms could be that TAM-derived CCL22 promotes epithelialmesenchymal transition (EMT) and increases invasive properties of tumor cells. 31 In HCC, overexpression of forkhead box Q1 (FoxQ1) induced EMT and secretion CCL2, which increased TAM infiltration. Depletion of TAMs decreased FoxQ1-enhanced HCC metastasis, 32 demonstrating the positive feedback loop between HCC cells and TAMs for tumor metastasis. Activated macrophage conditioned medium down-regulated E-cadherin and shifted liver cancer cells (HepG2 cells) from epithelial morphology toward a mesenchymal phenotype. 33 Treatment with conditioned medium from murine TAMs also induced EMT of mouse hepatoma cells (Hepa1-6), showing higher mesenchymal markers and invasion, as well as cancer stem cell (CSC)-like properties and tumorigenicity. TAM-derived TGF-b was important for these TAM-induced EMT and CSC-like properties. 34 HCC MDSCs may utilize similar mechanisms to induce EMT.
CSCs, owing to their self-renewal and tumorinitiating capacity, are involved in tumor survival, chemoresistance, recurrence, and metastasis. Our group has observed a mechanistic link between TAMs and HCC CSCs. 35 We found that TAMs enhanced the human HCC CSCs phenotype, including higher stemnessrelated gene expression and sphere-forming capacity, resulting in larger tumor volume in vivo. This CSCpromoting effect was mediated by TAMs through the IL-6-and signal transduction and activator of transcription (STAT)3-signaling pathways. This effect was disrupted by tocilizumab, a humanized anti-IL6R antibody. MDSCs have also been shown to enhance cancer cell stemness and metastasis in ovarian carcinoma by microRNA101 and corepressor gene C-terminalbinding protein 2. 36 Hence, targeting TAMs and MDSCs could interrupt CSC-mediated tumor initiation and progression.
Myeloid Cells and HCC Immune Suppression

TAMs and Immune Suppression
The degree of immune suppression in the tumor microenvironment is associated with poor prognosis in HCC patients. In HCC patients, the density of antitumor inflammatory cells, including cytotoxic CD8 1 T cells and neutrophils, within the tumor is correlated positively with apoptotic tumor cells and patient survival. 37 However, the majority of HCC patients lack the infiltration of these antitumor inflammatory cells owing to the immune-suppressive environment in HCC. 38 In contrast, TAMs are abundant in the HCC microenvironment, and the frequencies of TAMs in the tumor are comparable to that in the nontumor or peritumor areas. 37 TAMs actively disrupt antitumor immunity. 5, 39, 40 TAMs suppress T-cell effector function through multiple mechanisms. Classically activated macrophages produce IL-12, which promotes T-helper (Th)1-cell activation. However, TAMs produce limited IL-12 and instead produce IL-10, which promotes Th2 cell development and reduces cytotoxic T lymphocytes (CTLs). 41 Moreover, TAMs produce chemokines CCL17, CCL18, and CCL22, which preferentially attract T regulatory (Treg) and Th2 cells to the tumor and, in turn, impair CTL activation. 42, 43 However, this mechanism has yet to be demonstrated in HCC. Increased tumor-infiltrating Treg correlates with poor prognosis in HCC patients, and the intratumoral prevalence of Treg is associated with high density of TAMs. 44 Additionally, Treg production of IL-10, IL-4, and IL-13 can promote differentiation of monocytes into immunosuppressive TAMs. 45 Therefore, a positive feedback loop may exist between TAMs and Treg cells that further enhance their immunosuppressive effects in HCC.
In hepatitis B virus (HBV)-associated HCC, TAMs expressed a high level of galectin-9. Binding of galectin-9 to T-cell immunoglobulin domain and mucin domain 3 (TIM-3) on T cells induces senescence of T cells. Blockade of TIM-3/galectin-9 signaling restored functionality of tumor-infiltrating effector T cells. 39 Hence, TAM galectin-9 and T-cell TIM-3 could be immunotherapeutic targets in patients with HBV-associated HCC. Indoleamine-pyrrole 2,3-dioxygenase (IDO), an immunomodulatory enzyme that suppresses T-cell responses, is also highly expressed in HCC TAMs. HCC-infiltrating CD69 1 T cells induce IDO expression in TAMs through IFN-c and TNF-a. TAMs-derived IDO, in turn, impairs T-cell proliferation and effector cytokine production, contributing to immunosuppression in HCC. 46 TAMs suppress T cells through expression of the coinhibitory molecule, B7-H1, to the ligand for programmed death 1 (PD-1) on T cells, reducing T-cell effector functions against tumor cells. B7-H1 levels in liver macrophages are higher in tumor-bearing mice than in normal mice, which, in turn, suppress T-cell activation. 47 Tumor-associated IL-10 and TNF-a contribute to induction of B7-H1 on HCC TAMs. Importantly, blocking B7-H1 on TAMs or PD-1 on T cells using neutralizing antibodies recovered effector T-cell function and antitumor activity. 5, 48 Therefore, targeting the immunosuppressive function of TAMs provides important therapeutic implications for treatment of HCC. Indeed, anti-PD-1-targeted agents are approved by the FDA to treat patients with melanoma and are currently in phase I clinical trial in HCC patients.
MDSCs and Immune Suppression
MDSCs inhibit T-cell responses through diverse mechanisms. First, MDSCs deplete nutrients, Larginine, and L-cysteine, necessary for T-cell function. MDSCs show increased activity of arginase, which depletes arginine and down-regulates CD3f chain on T cells, resulting in suppression of T-cell proliferation and cytokine production. 49 Cysteine is essential for T-cell activation. T cells lack the cystathionase that generates cysteine and therefore solely depend on exogenous cysteine. APCs import cystine and convert it to cysteine that is then exported outside of cells. MDSCs compete with APCs for cystine and limit the availability of cysteine in their extracellular environment by not exporting cysteine. The reduced extracellular cysteine caused by MDSCs results in impaired T-cell proliferation and activation. 50 MDSCs also generate oxidative stress through production of reactive oxygen species and reactive nitrogen species. These reactive species inhibit T-cell responses through reducing T-cell receptor (TCR)fchain expression, impairing IL-2 receptor signaling and disrupting TCR interaction with major histocompatibility complex. 51, 52 In human HCC, CD14 
HLA-DR
2 MDSCs, Tregs, and PD-1 1 exhausted T cells along with increased levels of immunosuppressive cytokines IL-10 and TGF-b, suggesting immune dysfunction in advanced HCC. 9 Thus, MDSCs and Tregs are important components of immunosuppressive milieu in HCC, and MDSCs can exert their immunosuppressive function through inducing Treg expansion.
Other mechanisms have been described, in which MDSCs affect T-cell function, survival, and trafficking. Similar to TAMs, MDSCs express galectin-9 that binds to TIM-3 on T cells, inducing T-cell apoptosis. 53 MDSCs also express ADAM17 that down-regulate Lselectin (CD62L) levels on T cells, limiting their homing to lymph nodes and tumors. 54 In a breast cancer mouse model, MDSCs (CD11b 1 Gr1
1
) could home to and accumulate in high numbers in the liver. Additionally, MDSCs interact with liver macrophages and cause their up-regulation of B7-H1, further strengthening the immunosuppressive phenotype. 47 MDSCs can also impair natural killer (NK) cell function. In human HCC, MDSCs (CD14 
HLA-DR
2/low
) inhibit NK cell cytotoxicity and cytokine release, which is mediated by the NKp30 receptor. 55 Tumor-derived IL-1b induces Ly6C-negative MDSCs, which also inhibit NK cell development and function. 56 In summary, MDSCs contribute to the immunosuppressive network through multiple mechanisms and are potential immunotherapy targets for HCC.
Myeloid Cells and HCC Therapy
Owing to the tumor-promoting and immunosuppressive roles of myeloid cells, there is great interest in targeting them to enhance the efficacy of conventional cancer therapy. A recently approved chemotherapeutic agent, trabectedin, not only targets tumor cells, but also induces rapid apoptosis in myeloid cells, whereas neutrophils and lymphocytes are not affected. 57 Noteworthy, although trabectedin has no effects on some sarcoma and ovarian cell lines in vitro, it still retained its efficacy on in vivo tumor growth from these lines, indicating that trabectedin-induced apoptosis of myeloid cells plays a key role in limiting tumor growth. 57 Trabectedin clinical trials reported reversible hepatotoxicity in human patients. 58 Trabectedin also exerts potent cytotoxicity on HepG2 liver cancer cells. 59 Therefore, trabectedin may be a promising therapy for HCC through targeting both cancer cells and myeloid cells. HCC is a male-predominant cancer with worse prognosis for men compared to women. 60 Estrogen, the primary female sex hormone, suppresses myeloid cell function in HCC. 61 Estrogen inhibited secretion of IL-6 from macrophages exposed to necrotic hepatocytes and reduced liver cancer risk in DEN-treated female mice.
14 Estrogen inhibited myeloid cell function, including reduced arginase activity, mannose receptor CD206 expression, and IL-10 production. Estrogen suppressed tumorpromoting myeloid cells through inhibiting Janus kinase (JAK)-STAT6 activation, leading to reduced tumor growth murine HCC models. 62 Hence, estrogen therapy may be useful in disrupting the development and function of myeloid cells in HCC. Myeloid cell elimination can be achieved by two well-studied agents: ZA and clodronate-containing liposome (clodrolip). ZA is an FDA-approved drug for bone metastasis, which specifically induces apoptosis of osteoclasts and macrophages. Clodrolip is a bisphosphonate clodronate-containing liposome that reduces myeloid cell number in tumors and circulating monocytes in peripheral blood. In a metastatic HCC mouse model, depletion of myeloid cells by ZA and clodrolip in combination with sorafenib significantly inhibited tumor progression, tumor angiogenesis, and lung metastasis, compared with sorafenib treatment alone. 19 Hence, targeting myeloid cells represents a point of further study as a possible adjuvant therapy to attenuate HCC progression.
Concluding Remarks
Myeloid cells in HCC are skewed to suppress antitumor immunity and support HCC progression (Fig. 2 and Table 1 ). Immunosuppressive effects of myeloid cells are one of the key factors limiting the efficacy of immunotherapies that require active antitumor immune responses. 63 Therefore, disrupting these cells could counteract the immunosuppressive network and impede tumor progression. Potential methods to inhibit myeloid cells in HCC include: (1) target molecular pathways involved with suppressing effector cell function or promoting tumor growth; (2) target tumor factors that induce immunosuppressive myeloid cells from bone marrow progenitors; (3) repolarize them to become active APCs that stimulate antitumor immunity; and (4) induce apoptosis of myeloid cells or block trafficking to lymphoid organs and tumors. Targeting these common pathways utilized by immunosuppressive and tumor-promoting myeloid cells could provide novel therapeutic strategies to better treat HCC patients.
